Mclean, VA – According to filings with the U.S. Securities and Exchange Commission, Perthera is raising $5,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Albert Kelley played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Perthera
Perthera AI is an oncology company that has pioneered the use of advanced multi-omic molecular analysis combined with a comprehensive data lake of patient specific outcomes and medical history to advise doctors & patients on optimal treatment options through the Oncology Operating System. Perthera uses AI to identify the best drugs available for that individual, giving patients a performance prediction score for every available therapeutic. The Perthera method and Oncology OS have been published and clinical proven to increase survival rates for thousands of patients, and are the best resource available today for oncologists in their treatment decision-making process. Pertheras clients & partners include Mayo Clinic, Pfizer, AstraZeneca, Novartis, the Department of Defense, and many others.

To learn more about Perthera, visit http://perthera.com/

Contact:
Albert Kelley, Chief Executive Officer
703-286-0780
https://www.linkedin.com/in/albertkelley51/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved